Palvella Therapeutics (PVLA) to Release Earnings on Monday

Key Points

• Q4 2025 earnings: Palvella is expected to report Q4 2025 before the market opens on March 30, 2026, with analysts projecting a loss of ($0.95) per share and an earnings call set for March 31 at 9:30 AM ET.
• Insider and institutional activity: COO Kathleen Goin sold 4,302 shares for about $507,593 while Director George M. Jenkins bought 4,000 shares and now owns 187,171 shares; insiders own 20.50% and institutional/hedge fund ownership is 40.11%.
• Analyst sentiment and stock context: The consensus rating is "Buy" with an average target of $184.87; the stock trades near $112.50 (market cap ≈ $1.33B) with a 12‑month range of $18.23–$151.18.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter. Parties can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Palvella Therapeutics Stock Down 1.2%

Shares of PVLA opened at $112.50 on Monday. The company has a 50-day moving average price of $103.11 and a two-hundred day moving average price of $88.67. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -42.78 and a beta of -0.31. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George M. Jenkins purchased 4,000 shares of the company's stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Vanguard Group Inc. lifted its position in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company's stock worth $31,010,000 after buying an additional 330,847 shares in the last quarter. State Street Corp increased its position in Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company's stock valued at $44,010,000 after acquiring an additional 283,211 shares in the last quarter. Millennium Management LLC acquired a new stake in Palvella Therapeutics in the 1st quarter valued at about $7,553,000. Artisan Partners Limited Partnership bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $22,143,000. Finally, First Light Asset Management LLC raised its stake in shares of Palvella Therapeutics by 30.9% in the fourth quarter. First Light Asset Management LLC now owns 709,141 shares of the company's stock worth $74,226,000 after acquiring an additional 167,597 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PVLA has been the subject of a number of recent research reports. Chardan Capital reissued a "buy" rating and issued a $210.00 target price on shares of Palvella Therapeutics in a report on Monday, March 16th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. BTIG Research upped their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, Canaccord Genuity Group lifted their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the company a "buy" rating in a report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Palvella Therapeutics has an average rating of "Buy" and a consensus target price of $184.87.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.